Search Results
Your search for ,maY matches 16767 pages
Showing 9151 - 9200Update on ATLAS Trial of Axitinib as Adjuvant Treatment for Patients at High Risk of Renal Cell Carcinoma Recurrence After Surgery
Pfizer recently announced that the independent data monitoring committee for the phase III ATLAS trial, which is evaluating axitinib (Inlyta) as adjuvant therapy for patients at high risk of recurrent renal cell carcinoma (RCC) after nephrectomy, recommended stopping the trial at a planned interim...
ASCO Clinical Practice Guideline Update: Fertility Preservation in Patients With Cancer
As reported in the Journal of Clinical Oncology by Kutluk Oktay, MD, PhD, of Yale University School of Medicine, and colleagues, ASCO has issued a clinical practice guideline update on fertility preservation in adults and children with cancer. The update was informed by an update panel systematic...
Following Nutrition and Exercise Guidelines May Prolong Survival in Stage III Colon Cancer
A diet high in whole grains, fruits, and vegetables—along with exercise and maintaining a healthy body weight—can improve the 5-year survival rate for patients with stage III colorectal cancer, according to a new report published by Van Blarigan et al in JAMA Oncology. The findings...
Nut Consumption in Patients With Stage III Colon Cancer
People with stage III colon cancer who regularly eat tree nuts are at significantly lower risk of cancer recurrence and mortality than those who don’t, according to findings published by Fadelu et al in the Journal of Clinical Oncology.1 Study Findings The study followed 826 participants in the...
AACR 2018: Boosting T-Cell Memory May Result in Longer-Lasting Responses in Patients Treated With Checkpoint Blockade Immunotherapies
Some T cells have excellent memories. These subtypes—known as memory T cells—may explain why some immunotherapies are more effective than others and could potentially lead to researchers designing more effective studies using combination checkpoint blockade treatments, according to...
AACR 2018: New Liquid Biopsy–Based Cancer Model Reveals Data on Chemoresistance in SCLC
Small cell lung cancer (SCLC) accounts for 14% of all lung cancers and is often rapidly resistant to chemotherapy, resulting in poor clinical outcomes. Treatment has changed little for decades, but a study at The University of Texas MD Anderson Cancer Center offers a potential explanation for...
FDA Approves Fostamatinib Disodium Hexahydrate for Chronic Immune Thrombocytopenia in Adult Patients
On April 17, the U.S. Food and Drug Administration (FDA) approved fostamatinib disodium hexahydrate (Tavalisse) for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. Fostamatinib is an oral spleen ...
An Inspiring Experience at Cancer Control for Primary Care Course in Bhutan
I’ll admit it. When I was first asked if I would chair the Cancer Control for Primary Care (CCPC) Course in Bhutan, I immediately exclaimed yes... and then sheepishly went to look up where exactly Bhutan was on a map. For the uninitiated, Bhutan is a country nestled between India and Tibet in the...
ASCO Honors Leaders in Cancer Care With 2018 Special Awards
ASCO and ASCO’s Conquer Cancer Foundation are proud to recognize the winners of ASCO’s Special Awards and Conquer Cancer’s Women Who Conquer Cancer Mentorship Awards. The recipients of these awards include researchers, patient advocates, and global oncology leaders who have worked to transform...
A Clinician’s Guide to Treating Patients With Glioblastoma
Glioblastoma, a grade 4 astrocytoma, is the most common and most aggressive form of primary brain tumors in adults. The most recent guidance on molecular profiling, diagnostic and prognostic factors, and treatments for newly diagnosed and recurrent diseases was described in the Journal of Oncology ...
A Career Based on Service: Both Medical and Military
For this installment in the Living a Full Life series of articles, Edith Peterson Mitchell, MD, was interviewed by Guest Editor Jame Abraham, MD, FACP. Dr. Mitchell is Clinical Professor of Medicine and Medical Oncology in the Division of Medical Oncology at Thomas Jefferson University as well as ...
Modest Weight Loss Reduces Breast Cancer Risk
Evidence of the numerous health benefits of weight loss continues to mount, and the hope is that doctors and patients are listening. A large observational study presented at the 2017 San Antonio Breast Cancer Symposium showed that weight loss of more than 5% is associated with a significantly lower ...
Expert Point of View: C. Kent Osborne, MD
C. Kent Osborne, MD, Director of the Dan L. Duncan Cancer Center at Baylor College of Medicine, Houston, and moderator of a press conference where the EMBRACA findings were presented, shared his thoughts on the study. While a few months’ improvement in the risk of disease progression may seem...
Meeting the Challenges of Providing Long-Term Psychosocial Care for Cancer Survivors
Focusing on the first year after a cancer diagnosis is necessary, but not sufficient, for delivering care to cancer survivors, according to Deborah Mayer, PhD, RN, Director of Cancer Survivorship at the UNC Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill....
Investigational in Vitro Diagnostics in Oncology Trials: Streamlined Submission Process for Study Risk Determination
On April 16, 2018, the U.S. Food and Drug Administration (FDA) issued a draft guidance, “Investigational in Vitro Diagnostics in Oncology Trials: Streamlined Submission Process for Study Risk Determination,” to describe for sponsors of certain oncology trials an optional streamlined...
AACR 2018: Short-Acting Calcium Channel Blockers Associated With Increased Risk of Pancreatic Cancer in Postmenopausal Women
Calcium channel blockers (CCBs)—specifically the short-acting form of CCBs, which are prescribed to treat high blood pressure—were associated with an increased risk of pancreatic cancer in postmenopausal women, according to a study presented at the American Assocation for Cancer...
Efforts to Make Tobacco Cessation in Cancer Survivors Standard Practice
It is well established that smoking increases the risk for developing cancer, but when it comes to tobacco cessation in the cancer survivor population, should oncologists be stepping in, and what resources should they be using? Graham W. Warren, MD, PhD, posed these questions to the audience at the ...
AACR 2018: Prototype Assays Suggest Highly Specific Blood Test to Screen for Cancer Is Feasible
Initial findings from the Circulating Cell-Free Genome Atlas (CCGA) study showed that prototype sequencing assays tested in this analysis may facilitate the development of a highly specific blood test for early cancer detection, according to data presented at the American Association for Cancer...
Expert Point of View: Christopher J. Recklitis, PhD, MPH
Christopher J. Recklitis, PhD, MPH, of Dana-Farber Cancer Institute and Harvard Medical School, called the results “instructive.” He said the study highlights the need for integrating mental health care into survivorship medical care. “We’re going to have to think about suicide prevention...
Elevated Suicide Risk Among Head and Neck Cancer Survivors Demands More Integrated Psychosocial Care
In general, the risk of suicide among cancer survivors is about 50% higher than in the general population, but this risk is especially elevated among survivors of head and neck cancer, according to research presented by Nosayaba Osazuwa-Peters, BDS, MPH, CHES, of the Department of...
Lower-Dose Radiation in HPV-Positive Head and Neck Cancers After Induction Chemotherapy
The results of a phase II clinical trial suggest that patients with head and neck cancers associated with the human papillomavirus (HPV) may receive significantly lower doses of radiation safely and effectively after response to induction chemotherapy.1 These findings from the OPTIMA study,...
Enormous Cost of Failure to Screen Heavy Smokers for Lung Nodules
In 2011 the American College of Radiology Imaging Network (ACRIN) group published its publicly funded study of three annual screening chest computed tomography (CT) scans among heavy smokers aged 55 to 74.1 The results remain the first and only screening study for any cancer demonstrating a...
2018 Treatment Algorithm for Metastatic HER2-Positive Breast Cancer
How should clinicians position anti-HER2 agents and also incorporate endocrine therapies in the treatment of metastatic HER2-positive breast cancer? At the 2018 Miami Breast Cancer Conference, this question was explored by Sunil Verma, MD, Medical Director of the Tom Baker Cancer Center and...
AACR 2018: Selective Inhibitor Shows Early Promise in Patients With RET-Altered Cancers
BLU-667, a next-generation inhibitor that selectively targets the oncogenic receptor tyrosine kinase RET, was well tolerated and had broad clinical benefit in patients with advanced cancer that had progressed on previous therapies, including multikinase inhibitor therapy. Proof-of-concept data from ...
AACR 2018: Children With Nonchromosomal Birth Defects May Face Higher Risk of Several Childhood Cancers
Children with nonchromosomal birth defects—such as congenital heart disease—had a significantly higher risk of developing childhood cancer than children who did not have birth defects, according to a study presented at the 2018 American Association for Cancer Research (AACR) Annual...
Minimal Residual Disease and Risk Stratification in Acute Myeloid Leukemia
In an analysis of the UK National Cancer Research Institute AML17 trial reported in the Journal of Clinical Oncology, Freeman et al found that detection of measureable/minimal residual disease (MRD) after first induction in acute myeloid leukemia (AML) may be prognostically equivalent to partial...
Wait for Diagnostic Testing and Effect on Outcomes in Patients With Cancer
The longer patients with a positive screening result wait for diagnostic testing, the worse their cancer outcomes may become, according to a literature review of breast, cervical, colorectal, and lung studies published by Doubeni et al in CA: A Cancer Journal for Clinicians led by researchers at...
Epacadostat Combined With Pembrolizumab in Patients With Unresectable or Metastatic Melanoma
On April 6, an external data monitoring committee commented on results from the phase III ECHO-301/KEYNOTE-252 trial of the investigational IDO1 inhibitor epacadostat plus pembrolizumab (Keytruda) in patients with unresectable or metastatic melanoma. The committee determined that the study did not...
FDA Accepts New Drug Application, Grants Priority Review for Duvelisib in CLL/SLL and Follicular Lymphoma
On April 9, the U.S. Food and Drug Administration (FDA) accepted for filing with Priority Review a new drug application (NDA) for the oral agent duvelisib, a first-in-class, dual inhibitor of phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma. The NDA is seeking full approval for duvelisib in...
Clinical Hold Lifted on U.S. Studies of BPX-501
On April 11, Bellicum Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on studies of BPX-501 in the U.S. The decision follows consultation with the FDA and agreement on amendments to the study protocols including guidance on monitoring...
ELCC 2018: Canadian Study Shows Coordinating Nurses Can Improve Patients’ Quality of Life and Satisfaction During Lung Cancer Treatment
Investing in the continuity of care for lung cancer patients can bring tremendous benefits in terms of patient satisfaction and quality of life. In Quebec, this investment has taken the form of a dedicated role on the medical team: The Pivot Nurse in Oncology (PNO). A study presented by Kassouf et...
ASCO Clinical Practice Guideline: Optimizing Anticancer Therapy in Metastatic Noncastrate Prostate Cancer
As reported in the Journal of Clinical Oncology by Michael J. Morris, MD, of Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, and colleagues, ASCO has released a clinical practice guideline on optimizing anticancer therapy in men with metastatic noncastrate prostate cancer. To...
ESMO Releases Comments on Findings From the Pan-Cancer Atlas
The European Society for Medical Oncology (ESMO) welcomes the latest reports from The Cancer Genome Atlas (TCGA) as a major resource for researchers across the world and calls for increased across-the-board commitment to translate these efforts into medical advances for the benefit of patients with ...
Updated ASTRO Guideline for Palliative Radiotherapy in Lung Cancer
The American Society for Radiation Oncology (ASTRO) has issued an update to its clinical guideline for the use of palliative-intent radiation therapy for patients with incurable non–small cell lung cancer (NSCLC). Reflecting new evidence from randomized clinical trials, the guideline now...
Notch Signaling and Treatment With Vismodegib in Basal Cell Carcinoma
A study by Eberl et al in Cancer Cell has pinpointed a mechanism that controls how basal cell cancers respond to treatment and offers new ideas for controlling this disease. Basal cell carcinomas are incredibly common—somewhere between 1 million to 3 million diagnosed each year—and...
FDA and EMA Accept Regulatory Submissions for Dacomitinib in Metastatic NSCLC With EGFR-Activating Mutations
On April 4, Pfizer Inc announced that the U.S. Food and Drug Administration (FDA) accepted the company’s new drug application and granted Priority Review for dacomitinib, a pan-human epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, for the first-line treatment of...
Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer
In a retrospective cohort study reported in JAMA Oncology, Cercek et al found evidence supporting the use of total neoadjuvant therapy as an effective option in locally advanced rectal cancer. Study Details The study involved data on 811 patients presenting with locally advanced rectal cancer (T3 ...
Sarcoma Foundation of America Partners With ASCO’s Conquer Cancer Foundation to Fund a 2018 Young Investigator Award
The Sarcoma Foundation of America (SFA) and Conquer Cancer have been working together for 13 years to fund cutting-edge sarcoma research. Most recently, the SFA joined forces with Conquer Cancer to support a 2018 Young Investigator Award (YIA) in sarcoma. This grant will provide 1 year of crucial...
How to Respond to a Patient’s Discriminatory Request for a Different Clinician
Some patients may make discriminatory requests for a different clinician for their health care.1-5 These individuals may want to avoid treatment with clinicians of a certain race, religion, gender, sexual orientation, or national origin. Oncologists are not exempt from this type of patient...
Is CAR T-Cell Therapy Setting a New Standard of Care in Lymphoma?
Data presented at the 2017 American Society of Hematology (ASH) Annual Meeting & Exposition on the longer-term follow-up analysis of results from the ZUMA-1 trial investigating the effectiveness of axicabtagene ciloleucel (Yescarta) in patients with refractory non-Hodgkin lymphoma (NHL) showed...
Maura Dickler, MD, Appointed Vice President of Late Phase Development at Lilly Oncology
ELI LILLY AND COMPANY announced that Maura Dickler, MD, a breast cancer clinical researcher at the Breast Medicine Service at Memorial Sloan Kettering Cancer Center (MSK), will join Lilly Oncology as Vice President of Late Phase Development in early May 2018. Dr. Dickler is currently Section Head ...
Future Looks Brighter for Treatment of Cholangiocarcinoma
THE INCIDENCE of cholangiocarcinoma is rising, and effective therapies are urgently needed. Several classes of experimental molecularly targeted agents might meet this challenge, according to Robin Kate Kelley, MD, Associate Professor of Medical Oncology and leader of the clinical trials program in ...
Emerging Thoughts About the Immune Landscape in Pancreatic Cancer
LONG-TERM SURVIVORS of pancreatic cancer display evidence of enhanced tumor-specific T-cell responses that are associated with unique neoepitope quality but not quantity, according to Steven D. Leach, MD, Director of the Norris Cotton Cancer Center and the Preston T. and Virginia R. Kelsey...
Four Years Posttreatment, Exercise Improves Physical Activity Levels, Reduces Fatigue in Patients With Breast and Colon Cancers
IN PATIENTS WITH breast and colon cancers, a physical exercise intervention conducted during adjuvant chemotherapy improved total physical activity levels 4 years after treatment, with a trend toward less fatigue, according to a follow-up study from the randomized multicenter PACT study, presented...
Greater Understanding of Family Dynamics May Help Cancer Teams Guide, Support Patients
WHETHER THEY are parents themselves or dealing with their own parents, patients with cancer often look to their health-care team to help guide these relationships, but data on how best to help are lacking, according to two poster presentations at the 2018 American Psychosocial Oncology Society...
Anti–PD-1 Immunotherapy in Previously Treated Gastric Cancer
As reported in JAMA Oncology by Fuchs et al, pembrolizumab (Keytruda) showed activity in patients with previously treated advanced gastric and gastroesophageal junction cancer in the phase II KEYNOTE-059 trial. Study Details In the study, 259 patients from sites in 16 countries who had disease...
How Will ctDNA Assays Aid in Managing Breast Cancer?
CIRCULATING TUMOR DNA (ctDNA) assays are now commercially available for use in lung cancer and melanoma, where they can identify the presence of specific mutations that drive treatment selection. In breast cancer, ctDNA remains more of a research tool, but this is poised to change. At the 2018...
Expert Point of View: Aaron Richard Hansen, BSc, MBBS (Hon), FRACP
“FOR THIS RARE tumor with a paucity of data, all we have are phase II trials to make treatment selection,” said invited discussant Aaron Richard Hansen, BSc, MBBS (Hon), FRACP, of the Princess Margaret Hospital, Toronto. “For patients with de novo metastatic disease or relapse after definitive...
Vinflunine May Benefit Selected Patients With Penile Cancer
PENILE CANCER is rare, outcomes remain poor, and there are few data from randomized trials to guide treatment decisions. However, in the small phase II VinCaP study, presented at the 2018 Genitourinary Cancers Symposium, 45.5% of patients with advanced or metastatic penile cancer had a clinical...
GU Symposium Focuses on Prognostic Model in Urothelial Cancer, Novel Therapies for Prostate and Kidney Cancers
THE 2018 GENITOURINARY Cancers Symposium hosted an international audience of oncologists and other stakeholders to hear about the latest advances in the field. We have included coverage of many of the top news stories from the meeting in previous issues of The ASCO Post. Here are summaries of a few ...
